Genmab A/S Share Price & Technical Analysis
GMAB · $26.87 (-0.67%)
Healthcare / Biotechnology
$26.87
-0.67%
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervic…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
2% return in May, -2% avg return in past 3 year May month.
-15% return in 2026, -8% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 4% | -10% | -9% | -3% | 2% | – | – | – | – | – | – | – | -15% |
| 25 | -7% | 19% | -16% | 10% | -1% | -5% | 6% | 16% | 19% | -7% | 13% | -5% | 43% |
| 24 | -12% | 0% | 4% | -7% | 1% | -12% | 13% | -2% | -12% | -8% | -5% | -4% | -44% |
| 23 | -9% | -4% | 1% | 10% | -5% | -3% | 9% | -6% | -9% | -18% | 11% | 1% | -21% |
| 22 | -14% | -3% | 7% | -3% | -12% | 7% | 11% | 1% | -7% | 15% | 19% | -9% | 11% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Neutral
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$16.58B
P/E ratio
20.62
52W high
$35.43
52W low
$20.23
Volume
12,05,430
Beta
0.69
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Genmab A/S share price today?
- Genmab A/S (GMAB) last traded around $26.87 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GMAB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GMAB. Download the app for real-time alerts.
- How can I analyze Genmab A/S stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.